{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T06:07:16Z","timestamp":1778738836112,"version":"3.51.4"},"reference-count":39,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100017695","name":"Health Commission of Hunan Province","doi-asserted-by":"publisher","award":["202206012608"],"award-info":[{"award-number":["202206012608"]}],"id":[{"id":"10.13039\/100017695","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2024JJ8254"],"award-info":[{"award-number":["2024JJ8254"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.gastrohep.2025.502432","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T03:55:11Z","timestamp":1742183711000},"page":"502432","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of biologic therapy for Crohn's disease: An overview of meta-analyses and systematic reviews"],"prefix":"10.1016","volume":"48","author":[{"given":"Ping","family":"Jiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunchen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jidong","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangxiang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinhui","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cuicui","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gastrohep.2025.502432_bib0200","first-page":"293","article-title":"Comparing adalimumab and infliximab in the prevention of postoperative recurrence of Crohn's disease: a systematic review and meta-analysis","volume":"36","author":"Gangwani","year":"2023","journal-title":"Ann Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502432_bib0205","doi-asserted-by":"crossref","first-page":"792","DOI":"10.2174\/1389450121666191218123203","article-title":"Biologic therapy in Crohn's disease \u2013 what we have learnt so far","volume":"21","author":"Majchrzak","year":"2020","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.gastrohep.2025.502432_bib0210","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10151-019-1926-2","article-title":"Colorectal cancer in inflammatory bowel disease: review of the evidence","volume":"23","author":"Keller","year":"2019","journal-title":"Tech Coloproctol"},{"key":"10.1016\/j.gastrohep.2025.502432_bib0215","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1136\/flgastro-2021-101881","article-title":"Biologics recommendations in the ECCO guidelines on therapeutics in Crohn's disease: medical treatment","volume":"13","author":"Sriranganathan","year":"2022","journal-title":"Frontline Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502432_bib0220","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1590\/1806-9282.65.4.554","article-title":"Crohn's disease \u2013 treatment with biological medication","volume":"65","author":"Zaltman","year":"2019","journal-title":"Rev Assoc Med Bras (1992)"},{"key":"10.1016\/j.gastrohep.2025.502432_bib0225","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12876-022-02225-w","article-title":"Comparative effectiveness of second-line biological therapies for ulcerative colitis and Crohn's disease in patients with prior failure of anti-tumour necrosis factor treatment","volume":"22","author":"Hyun","year":"2022","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502432_bib0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ibd\/izy247","article-title":"Clinical practice guideline for the medical management of perianal fistulizing Crohn's disease: the Toronto Consensus","volume":"25","author":"Steinhart","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gastrohep.2025.502432_bib0235","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/1751-2980.12698","article-title":"Loss of response to scheduled infliximab therapy for Crohn's disease in adults: a systematic review and meta-analysis","volume":"20","author":"Zhang","year":"2019","journal-title":"J Dig Dis"},{"key":"10.1016\/j.gastrohep.2025.502432_bib0240","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1080\/1744666X.2019.1646127","article-title":"Overall and comparative safety of biologic and immunosuppressive therapy in inflammatory bowel diseases","volume":"15","author":"Holmer","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.gastrohep.2025.502432_bib0245","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.gastrohep.2025.502432_bib0250","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13643-017-0527-2","article-title":"Systematic review adherence to methodological or reporting quality","volume":"6","author":"Pussegoda","year":"2017","journal-title":"Syst Rev"},{"key":"10.1016\/j.gastrohep.2025.502432_bib0255","doi-asserted-by":"crossref","first-page":"j4008","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.gastrohep.2025.502432_bib0260","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jclinepi.2015.09.006","article-title":"A number of factors explain why WHO guideline developers make strong recommendations inconsistent with GRADE guidance","volume":"70","author":"Alexander","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.gastrohep.2025.502432_bib0265","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1093\/ibd\/izaa031","article-title":"Early vs late use of anti-TNFa therapy in adult patients with Crohn disease: a systematic review and meta-analysis","volume":"26","author":"Hamdeh","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gastrohep.2025.502432_bib0270","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1007\/s10620-021-06932-4","article-title":"Effectiveness and safety of ustekinumab in inflammatory bowel disease: a systematic review and meta-analysis","volume":"67","author":"Honap","year":"2022","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.gastrohep.2025.502432_bib0275","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1007\/s10620-023-08014-z","article-title":"Efficacy and safety of IL-12\/23 and IL-23 inhibitors for Crohn's disease: systematic review and meta-analysis","volume":"68","author":"Vuyyuru","year":"2023","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.gastrohep.2025.502432_bib0280","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3892\/etm.2023.11997","article-title":"Efficacy and safety of vedolizumab in the treatment of patients with inflammatory bowel disease: a systematic review and meta-analysis of randomized controlled trials","volume":"25","author":"Tang","year":"2023","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.gastrohep.2025.502432_bib0285","doi-asserted-by":"crossref","DOI":"10.1177\/17562848231166227","article-title":"Vedolizumab subcutaneous formulation maintenance therapy for patients with IBD: a systematic review and meta-analysis","volume":"16","author":"Hu","year":"2023","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502432_bib0290","doi-asserted-by":"crossref","first-page":"e30590","DOI":"10.1097\/MD.0000000000030590","article-title":"Efficacy and safety of vedolizumab for inflammatory bowel diseases: a systematic review and meta-analysis of randomized controlled trials","volume":"101","author":"Qiu","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.gastrohep.2025.502432_bib0295","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.dld.2019.05.002","article-title":"Effectiveness and safety of ustekinumab for Crohn's disease; systematic review and pooled analysis of real-world evidence","volume":"51","author":"Engel","year":"2019","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.gastrohep.2025.502432_bib0300","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/14712598.2020.1707800","article-title":"Effectiveness and safety of ustekinumab for the treatment of Crohn's disease in real-life experiences: a meta-analysis of observational studies","volume":"20","author":"Macaluso","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.gastrohep.2025.502432_bib0305","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.3390\/jcm11144202","article-title":"Real-world evidence of the effectiveness and safety of ustekinumab for the treatment of Crohn's disease: systematic review and meta-analysis of observational studies","volume":"11","author":"Rubin","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.gastrohep.2025.502432_bib0310","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/s40001-022-00817-6","article-title":"Adalimumab for induction of remission in patients with Crohn's disease: a systematic review and meta-analysis","volume":"27","author":"Yin","year":"2022","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.gastrohep.2025.502432_bib0315","first-page":"297","article-title":"Efficacy and safety of ustekinumab in the treatment of moderate to severe active Crohn's disease: a meta-analysis","volume":"30","author":"Song","year":"2021","journal-title":"Chin J Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502432_bib0320","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1186\/s12876-021-01883-6","article-title":"Systematic review and meta-analysis: real-world data rates of deep remission with anti-TNFalpha in inflammatory bowel disease","volume":"21","author":"Alipour","year":"2021","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502432_bib0325","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12051894","article-title":"Systematic review and meta-analysis of observational studies on the effectiveness and safety of ustekinumab among patients with inflammatory bowel disease in eastern and western countries","volume":"12","author":"Zhou","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.gastrohep.2025.502432_bib0330","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/apt.15685","article-title":"Systematic review and meta-analysis: efficacy and safety of early biologic treatment in adult and paediatric patients with Crohn's disease","volume":"51","author":"Ungaro","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2025.502432_bib0335","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/00365521.2020.1854848","article-title":"Efficacy of ustekinumab for active perianal fistulizing Crohn's disease: a systematic review and meta-analysis of the current literature","volume":"56","author":"Attauabi","year":"2021","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502432_bib0340","series-title":"Efficacy and safety of anti-\u03b14\u03b27 integrin-based biologics for the treatment of Crohn's disease: a meta-analysis","author":"Xiong","year":"2018"},{"key":"10.1016\/j.gastrohep.2025.502432_bib0345","series-title":"Meta-analysis of indirect comparison of the effectiveness and safety of ustekinumab and vedolizumab in the treatment of inflammatory bowel disease","author":"Zhao","year":"2021"},{"key":"10.1016\/j.gastrohep.2025.502432_bib0350","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/j.cgh.2018.01.030","article-title":"Efficacy of medical therapies for fistulizing Crohn's disease: systematic review and meta-analysis","volume":"16","author":"Lee","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502432_bib0355","first-page":"538","article-title":"Efficacy and safety of infliximab versus vedolizumab for inflammatory bowel disease: an indirect comparison meta-analysis","volume":"31","author":"Guo","year":"2022","journal-title":"Chin J Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502432_bib0360","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1038\/ctg.2015.63","article-title":"Loss of response to anti-TNFs: definition epidemiology, and management","volume":"7","author":"Roda","year":"2016","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.gastrohep.2025.502432_bib0365","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.autrev.2019.03.002","article-title":"Induction and maintenance treatment of inflammatory bowel disease: a comprehensive review","volume":"18","author":"Jeong","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.gastrohep.2025.502432_bib0370","first-page":"CD012878","article-title":"Adalimumab for induction of remission in Crohn's disease","author":"Abbass","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.gastrohep.2025.502432_bib0375","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1007\/s10620-019-05635-1","article-title":"Strategies to optimize anti-tumor necrosis factor therapy for perianal fistulizing Crohn's disease: a systematic review","volume":"64","author":"Tandon","year":"2019","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.gastrohep.2025.502432_bib0380","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/nrgastro.2017.104","article-title":"Perianal fistulizing Crohn's disease: pathogenesis, diagnosis and therapy","volume":"14","author":"Panes","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2025.502432_bib0385","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.crohns.2012.05.015","article-title":"Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease","volume":"7","author":"Schreiber","year":"2013","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.gastrohep.2025.502432_bib0390","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.cgh.2022.07.032","article-title":"Comparative risk of serious infections with biologic agents and oral small molecules in inflammatory bowel diseases: a systematic review and meta-analysis","volume":"21","author":"Solitano","year":"2023","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570525000974?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570525000974?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T05:07:38Z","timestamp":1778735258000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0210570525000974"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0210570525000974"],"URL":"https:\/\/doi.org\/10.1016\/j.gastrohep.2025.502432","relation":{},"ISSN":["0210-5705"],"issn-type":[{"value":"0210-5705","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of biologic therapy for Crohn's disease: An overview of meta-analyses and systematic reviews","name":"articletitle","label":"Article Title"},{"value":"Gastroenterolog\u00eda y Hepatolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastrohep.2025.502432","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"502432"}}